ReviewJACC. Cardiovascular interventions2021
The Art of SAPIEN 3 Transcatheter Mitral Valve Replacement in Valve-in-Ring and Valve-in-Mitral-Annular-Calcification Procedures.
Review in JACC. Cardiovascular interventions, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Mitral Valve Leaflet Modification: A Working Group Position Statement on Best Practices and Step-by-Step Guide.JACC. Cardiovascular interventions · 2026Guideline
- 5-Year Outcomes of Anterior Mitral Leaflet Laceration to Prevent Outflow Obstruction.JACC. Cardiovascular interventions · 2024Trial
- Morphological Variation in the Human Mitral Valve Using Statistical Shape Modelling.Annals of biomedical engineering · 2026Article
- Failure Mechanisms in Off-Label Electrosurgery Devices for BASILICA, LAMPOON, and SESAME.JACC. Cardiovascular interventions · 2026Article
- Current Evidence, Emerging Evidence, and Decision-Making: An Algorithm for Leaflet Modification Procedures.JACC. Cardiovascular interventions · 2026Review
- First-in-Human Use of Intravascular Lithotripsy to Facilitate Mitral Balloon Commissurotomy After Prior Annuloplasty Band Repair.JACC. Case reports · 2026Article
- Annular Reduction by Cinching With TEER in Commissure in Conventionally Inappropriate Ring for Transcatheter Valve.JACC. Case reports · 2025Article
- Transesophageal Echocardiography in Transcatheter Mitral Valve Replacement.Journal of clinical medicine · 2025Review
- Left Atrial Embolization During Transcatheter Mitral Valve in Mitral Annular Calcification: Successful Percutaneous Bailout Using an Atrial Septal Defect Occluder.JACC. Case reports · 2025Article
- Double-layer horizontal cross sutures for intra-atrial mitral valve implantation: An effective surgical method for severe mitral annular calcification.JTCVS techniques · 2023Article
- Transcatheter Mitral Valve Replacement in Failed Bioprosthetic Valve, Ring, and Mitral Annular Calcification Associated Mitral Valve Disease Using Balloon Expandable Transcatheter Heart Valve.Methodist DeBakey cardiovascular journal · 2023Review
- Redo transcatheter mitral valve replacement in mitral annular calcification.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2022Article
- Assessing the Hemodynamic Impact of Anterior Leaflet Laceration in Transcatheter Mitral Valve Replacement: AnFrontiers in cardiovascular medicine · 2022Article
- Imaging in Transcatheter Mitral Valve Replacement: State-of-Art Review.Journal of clinical medicine · 2021Review
- Role of computed tomography in transcatheter coronary and structural heart disease interventions.REC, interventional cardiologyArticle
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
The SAPIEN 3 is the only transcatheter heart valve commercially available for compassionate transcatheter mitral valve replacement in patients with previous mitral surgical rings and mitral annular calcification (valve in ring [VIR] and valve in mitral annular calcification [VIM]). Reported outcomes have been inconsistent or poor. The review provides an overview of the authors' approach to achieve largely consistent results despite the intrinsic limitations of SAPIEN 3 VIM and VIR. The approach includes bedside modifications of the valve implant, the delivery system, and of the cardiac substrate itself. Until purpose-built devices are readily available, VIR and VIM procedures will require aggressive multidisciplinary cooperation, meticulous planning and execution, and postprocedure management by experienced, high-volume operators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.